Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00369174 · ClinicalTrials.gov registry record · Phase 2
Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00369174: Completed Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT00369174 is a Phase 2 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 25 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00369174, a Phase 2 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leukoplakia
Interventions
- OTHER laboratory biomarker analysis
- DRUG rosiglitazone maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2006-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00369174
The ClinicalTrials.gov registry entry for NCT00369174 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which laboratory biomarker analysis is the first listed.
NCT00369174 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00369174 about?
NCT00369174 is a clinical study titled "Rosiglitazone Maleate in Treating Patients With Oral Leukoplakia". This phase II trial is studying how well rosiglitazone works in preventing oral cancer in patients with oral leukoplakia. Chemoprevention is the use of certain drugs to keep cancer from forming, growing, or coming back. The use of rosiglitazone may keep cancer from forming in patients with oral leuk...
What is the current status of trial NCT00369174?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2006-06.
What interventions are being tested in trial NCT00369174?
The interventions under investigation include: laboratory biomarker analysis (OTHER), rosiglitazone maleate (DRUG).
Who is sponsoring clinical trial NCT00369174?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.